Abstract 1859P
Background
Cognitive impairment (CI) is a common late effect after cancer treatment, for which effective treatment is lacking. Goal Management Training (GMT) is a validated cognitive remediation protocol reported to improve cognition including perceived daily life executive functioning, in neurological conditions. However, GMT has never been examined in cancer survivors, nor been presented in a digital format. This study examined the feasibility and acceptability of digital GMT in cervical cancer survivors (CCS) with subjective and/or objective CI.
Methods
We invited 65 CCS with CI to participate. Participants were randomized in a 1:1 ratio between digital GMT and a computerized cognitive training (CCT) program (BrainHQ). GMT consists of six weekly group-based modules encompassing discussion of participants’ real-life cognitive deficits, practice on tasks of attention and self-monitoring, as well as homework assignments. BrainHQ is a web-based training platform with exercises targeting several cognitive domains. For six weeks, participants joined digital training sessions of one hour twice a week. The primary endpoint was attendance, and participants attending ≥80% of the sessions were categorized as completers. Acceptability was evaluated 1 week post-intervention using the Client Satisfaction Questionnaire-8 (CSQ-8). A total CSQ-8 score ≥ 26 was defined as “very satisfied”, scores 20-25 as “satisfied”, and scores <20 as “not satisfied”.
Results
33 CCS with a median age of 50.0 years (range 35-67) were randomized to either GMT (N = 16) or CCT (N = 17). In the GMT group, all participants completed the intervention (100%), compared to 15 (88%) in the CCT group. Median CSQ-8 in the GMT and CCT group was 25 (SD 3.7, range 18-31) and 24 (SD 3.1, range 19-30) respectively. Participants in both groups reported a high level of satisfaction as 40% reported being “very satisfied” and 53% “satisfied”.
Conclusions
A digital cognitive training program such as GMT is feasible with a high level of compliance and satisfaction in CCS and is suitable to be tested in a larger study. Exploratory analyses of neuropsychological assessments in our study will provide important preliminary data on the efficacy of improving cognitive function in CCS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jan Kåre Heiberg and Marthe Vildåsen.
Disclosure
K. lindemann: Financial Interests, Institutional, Research Grant, Grants or contracts, paid to institution: GSK; Financial Interests, Institutional, Advisory Board, Participation on Data Safety Monitoring/advisory board: Eisai, MSD, Nycode, AstraZeneca, GSK. All other authors have declared no conflicts of interest.
Resources from the same session
1594P - End-of-life hospital cancer care in the COVID-19 era: A retrospective population-based study in the Netherlands
Presenter: Ellis Slotman
Session: Poster session 05
1595P - Incidence and characterization of end-of-life (EoL) systemic anticancer therapy (SACT) in melanoma patients (pts): A monocentric experience
Presenter: Silvia Buriolla
Session: Poster session 05
1596P - Exploring the economic impact of palliative care in oncology at the end of life
Presenter: Sarah Gomes
Session: Poster session 05
1597P - Improving in-hospital end-of-life care (EOLC) for oncology patients in a tertiary cancer centre
Presenter: Conor Moloney
Session: Poster session 05
1598P - Differences in referral patterns to the palliative care team among specialized physicians in patients with terminal cancer
Presenter: Hyun Jeong Shim
Session: Poster session 05
1599P - Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study
Presenter: Alessandro Leonetti
Session: Poster session 05
1600P - Sarcopenia, depression, and poor health perception among cancer patients registered in an oncology center in Pakistan
Presenter: Sobia Yaqub
Session: Poster session 05
1601P - Relationship between CT and ultrasonography-based sarcopenia and hematologic toxicity in patients with cancer receiving chemotherapy
Presenter: Gurkan Guner
Session: Poster session 05
1602P - Simulation training for compassionate extubation in the pediatric intensive care unit
Presenter: Nicole Fernandez
Session: Poster session 05
1603P - The ability of the LACE index to predict 30-day readmissions in oncology patients
Presenter: Burcu Ulas Kahya
Session: Poster session 05